PM14

Phase 2Small molecule

PPharmaMar

PM14 is one of 93 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

Soft Tissue SarcomaRecruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

25 2

Keytruda

Merck & Co.

Phase 2

19 3

Avastin

Roche

Phase 2

10 4

Tecentriq

Roche

Phase 2

4 5

Beyfortus

BeiGene

Phase 2

3 6

Perjeta

Roche

Phase 2

2 7

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 8

Aldactone

Pfizer

Phase 2

1 9

Cyramza

Eli Lilly

Phase 2

1 10

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

Recruiting·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT05146440·195 enrolled

Patients With Advanced Solid Tumors1 trial

PM14 Administered Intravenously to Patients with Advanced Solid Tumors

Recruiting·PPharmaMar·Phase 1·NCT05076396·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PM14. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PM14 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PM14. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaMar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPharmaMar

PM14

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News